Wednesday, February 19, 2020 9:54:55 AM
SAM WHITEHEAD • FEB 18, 2020
A Metro Atlanta Biotech Company Is Working On A Coronavirus Vaccine
SAM WHITEHEAD • FEB 18, 2020
Farshad Guirakhoo, chief scientific officer at GeoVax, inspects cell culture samples in an incubator. It's here that scientists grow the starting material they hope to turn into a coronavirus vaccine.
Farshad Guirakhoo, chief scientific officer at GeoVax, inspects cell culture samples in an incubator. It's here that scientists grow the starting material they hope to turn into a coronavirus vaccine.
CREDIT SAM WHITEHEAD / WABE
https://www.wabe.org/a-metro-atlanta-biotech-company-is-working-on-a-coronavirus-vaccine/ SPONSORED CONTENT
SPONSORED CONTENT
SPONSORED CONTENT
2:04 | Play story Add to My List
The lab at GeoVax, a small biotech company in Smyrna, is loud. It’s outfitted with a complex ventilation system to make sure the viruses that scientists there work with don’t escape.
“[You] have to really make sure that you’re not [letting] anything outside,” said Farshad Guirakhoo, chief scientific officer of GeoVax.
Many of the vaccines made at the lab use the same starting material: a weakened form of the smallpox virus that can carry genetic information from other viruses.
Once injected, the vaccines produce molecules called virus-like particles. Unlike actual viruses, they’re not infectious, but they still look enough like actual viruses to build the body’s immune response.
“Next time they see the real virus, everything is ready for action and [ready to] get rid of the virus very quickly,” Guirakhoo said.
This kind of technology is called a vaccine platform, and it can be used to develop immunizations for many different viruses.
David Dodd, chief operating officer of GeoVax, said his company has used it to make vaccines for Ebola and HIV.
“Coronavirus, same thing,” Dodd said. “It’s what we refer to at times just to simplify as a ‘plug and play’ platform.”
As in, plug in the genetic information of the virus you want to fight, and you’re good to go.
Other companies are using similar technologies to develop vaccines against COVID-19, the pneumonia-like disease caused by the new coronavirus, some with the support of the federal government.
The U.S. Department of Health and Human Services announced a partnership with drug-maker Sanofi this week to help push along the company’s vaccine.
Dodd, however, thinks GeoVax has an edge: a partnership with a Chinese biotech company called BravoVax. It’s headquartered in Wuhan, the epicenter of the coronavirus outbreak.
“They have established good relationships with the Chinese [Center for Disease Control and Prevention], regulatory authorities and investors,” he said.
Dodd thinks those connections could help get GeoVax’s coronavirus vaccine to market faster. Still, he estimates it won’t be ready for at least two years.
COVID-19 has killed more than 1,800 people and sickened more than 73,000 others, most of them in China since it was first discovered late last year.
U.S. public health officials say the disease is showing no sign of slowing down and could even become seasonal, like the flu.
Dr. Robert Redfield, director of the Centers for Disease Control and Prevention, told CNN last week the new coronavirus is “probably with us beyond this season, beyond this year.”
Recent GOVX News
- GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine • GlobeNewswire Inc. • 04/04/2024 04:30:00 PM
- GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress • GlobeNewswire Inc. • 03/28/2024 01:00:00 PM
- GeoVax to Present at the 36th Annual Roth Conference • GlobeNewswire Inc. • 03/12/2024 01:00:00 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 03/11/2024 08:13:14 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/11/2024 04:15:24 AM
- GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System • GlobeNewswire Inc. • 03/06/2024 02:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/01/2024 09:08:47 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 09:05:14 PM
- GeoVax Reports 2023 Year-End Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 09:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:41:26 PM
- GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024 • GlobeNewswire Inc. • 02/22/2024 02:00:00 PM
- GeoVax to Present at the 2024 BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/19/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:01:35 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:38:25 PM
- GeoVax Announces Multiple Patent Issuances and Allowances • GlobeNewswire Inc. • 02/13/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 09:43:48 PM
- GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster • GlobeNewswire Inc. • 02/06/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/31/2024 06:13:27 PM
- GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement • GlobeNewswire Inc. • 01/29/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 09:03:40 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/12/2024 09:00:38 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM